secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001326110-26-000036
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio reports preliminary Q1 2026 net product revenue $44.2M, up 168% YoY, cash $381M
--------------------------------------------------------------------------------

- Preliminary Q1 2026 net product revenue ~$44.2M, up 168% YoY and 15% sequentially from $38.3M in Q4 2025.
- Cash, cash equivalents and marketable securities of $380.9M as of March 31, 2026.
- ANKTIVA unit sales volume increased 168% YoY; now approved in 5 jurisdictions covering ~34 countries.
- NCCN guidelines updated March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC papillary-only disease (Category 2A).
- Pivotal BCG-naive NMIBC CIS trial (QUILT-2.005) fully enrolled; supplemental BLA submission on track for 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/0001326110-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/ibrx-20260409.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer